Drugs / ABBV-444
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07284381 | Dec 2025 → Aug 2026 overdue | dry eye syndrome | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05878067 | Jun → Oct 2023 | dry eye syndrome | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284381 ↗ |
| Route | Other | “Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.” NCT05878067 ↗ |